Immuno-oncology has emerged over the past decade as an important breakthrough approach for cancer treatment. It aims at stimulating the patient’s immune system by enhancing its natural ability to fight diseases.

Seqalis™ has developed a unique solution for the monitoring of the T-cell receptor immune repertoires. This service stems from the recent work of Dr Javier Carrasco, clinical oncologist, and his team at the Laboratory of Translational Oncology (IPG/GHdC, Gosselies, BE).

Called qTCR-Seq, this quantitative unbiased technology platform enables to precisely explore and accurately characterize T cells immune response by sequencing their RNA and/or DNA.

The study of the T cells undoubtedly contributes to speed up the development of both new disruptive therapeutic drug candidates and related diagnostic approaches, e.g. the identification and the development of new biomarkers in the context of personalized medicine.